Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.

Janssen YF, Feitsma EA, Boersma HH, Alleva DG, Lancaster TM, Sathiyaseelan T, Murikipudi S, Delpero AR, Scully MM, Ragupathy R, Kotha S, Haworth JR, Shah NJ, Rao V, Nagre S, Ronca SE, Green FM, Aminetzah A, Sollie F, Kruijff S, Brom M, van Dam GM, Zion TC.

Open source

DOI
10.1016/j.vaccine.2022.01.043
Published
2022-01-31
Container
Vaccine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2022.01.043,
  title = {Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.},
  author = {Janssen YF and  Feitsma EA and  Boersma HH and  Alleva DG and  Lancaster TM and  Sathiyaseelan T and  Murikipudi S and  Delpero AR and  Scully MM and  Ragupathy R and  Kotha S and  Haworth JR and  Shah NJ and  Rao V and  Nagre S and  Ronca SE and  Green FM and  Aminetzah A and  Sollie F and  Kruijff S and  Brom M and  van Dam GM and  Zion TC.},
  year = {2022},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2022.01.043},
  url = {https://doi.org/10.1016/j.vaccine.2022.01.043}
}

RIS

TY  - JOUR
TI  - Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
AU  - Janssen YF
AU  -  Feitsma EA
AU  -  Boersma HH
AU  -  Alleva DG
AU  -  Lancaster TM
AU  -  Sathiyaseelan T
AU  -  Murikipudi S
AU  -  Delpero AR
AU  -  Scully MM
AU  -  Ragupathy R
AU  -  Kotha S
AU  -  Haworth JR
AU  -  Shah NJ
AU  -  Rao V
AU  -  Nagre S
AU  -  Ronca SE
AU  -  Green FM
AU  -  Aminetzah A
AU  -  Sollie F
AU  -  Kruijff S
AU  -  Brom M
AU  -  van Dam GM
AU  -  Zion TC.
PY  - 2022
JO  - Vaccine
DO  - 10.1016/j.vaccine.2022.01.043
UR  - https://doi.org/10.1016/j.vaccine.2022.01.043
ER  - 

APA

YF, J., EA, F., HH, B., DG, A., TM, L., T, S., S, M., AR, D., MM, S., R, R., S, K., JR, H., NJ, S., V, R., S, N., SE, R., FM, G., A, A., F, S., S, K., M, B., GM, V. D., & TC., Z. (2022). Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.. Vaccine. https://doi.org/10.1016/j.vaccine.2022.01.043

Source records